DERM
Journey Medical CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.81
P/S
1.96
EV/EBITDA
-27.97
DCF Value
$-8.44
FCF Yield
-10.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.3%
Operating Margin
-13.2%
Net Margin
-18.5%
ROE
-46.4%
ROA
-17.1%
ROIC
-14.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $16.1M | $-1.2M | $-0.05 |
| FY 2025 | $61.9M | $-11.4M | $-0.47 |
| Q3 2025 | $17.6M | $-2.3M | $-0.09 |
| Q2 2025 | $15.0M | $-3.8M | $-0.16 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.04
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.